Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research

[1]  A. Butte,et al.  Relating hepatocellular carcinoma tumor samples and cell lines using gene expression data in translational research , 2015, BMC Medical Genomics.

[2]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[3]  Andrew L. Kung,et al.  Computational Repositioning and Preclinical Validation of Pentamidine for Renal Cell Cancer , 2014, Molecular Cancer Therapeutics.

[4]  W. Bodmer,et al.  Cancer cell lines for drug discovery and development. , 2014, Cancer research.

[5]  Danyi Wen,et al.  Establishment and Characterization of 7 Novel Hepatocellular Carcinoma Cell Lines from Patient-Derived Tumor Xenografts , 2014, PloS one.

[6]  A. Butte,et al.  A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.

[7]  Joshua M. Stuart,et al.  The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.

[8]  Jiang Li,et al.  Large Scale Comparison of Gene Expression Levels by Microarrays and RNAseq Using TCGA Data , 2013, PloS one.

[9]  C. Sander,et al.  Evaluating cell lines as tumour models by comparison of genomic profiles , 2013, Nature Communications.

[10]  Jean-Pierre Gillet,et al.  The clinical relevance of cancer cell lines. , 2013, Journal of the National Cancer Institute.

[11]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[12]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[13]  Alexander A. Morgan,et al.  Computational Repositioning of the Anticonvulsant Topiramate for Inflammatory Bowel Disease , 2011, Science Translational Medicine.

[14]  Alexander A. Morgan,et al.  Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression Data , 2011, Science Translational Medicine.

[15]  Leming Shi,et al.  Similarities and Differences in the Expression of Drug-Metabolizing Enzymes between Human Hepatic Cell Lines and Primary Human Hepatocytes , 2011, Drug Metabolism And Disposition.

[16]  Joel Dudley,et al.  Matching Cancer Genomes to Established Cell Lines for Personalized Oncology , 2011, Pacific Symposium on Biocomputing.

[17]  Luc Girard,et al.  Lung cancer cell lines as tools for biomedical discovery and research. , 2010, Journal of the National Cancer Institute.

[18]  C. Bagi,et al.  Models of Hepatocellular Carcinoma and Biomarker Strategy , 2010, Cancers.

[19]  J. Minna,et al.  Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? , 2010, Lung cancer.

[20]  W. Huber,et al.  which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets , 2011 .

[21]  E. Raymond,et al.  [Targeted therapies in hepatocellular carcinoma]. , 2010, Presse medicale.

[22]  Brad T. Sherman,et al.  Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.

[23]  J. Marin,et al.  Chemotherapy in the treatment of primary liver tumours , 2008 .

[24]  D. Kell.  BMC Medical Genomics , 2008 .

[25]  W. Schoonen,et al.  Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. , 2007, Toxicology in vitro : an international journal published in association with BIBRA.

[26]  A. Butte,et al.  AILUN: reannotating gene expression data automatically , 2007, Nature Methods.

[27]  Adam Ertel,et al.  Pathway-specific differences between tumor cell lines and normal and tumor tissue cells , 2006, Molecular Cancer.

[28]  Shuguang Huang,et al.  Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data , 2006, BMC Genomics.

[29]  R. Sandberg,et al.  Assessment of tumor characteristic gene expression in cell lines using a tissue similarity index (TSI). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  T. Litman,et al.  A Serial Analysis of Gene Expression (SAGE) database analysis of chemosensitivity: comparing solid tumors with cell lines and comparing solid tumors from different tissue origins. , 2004, Cancer research.

[31]  J. Sahi,et al.  Induction of Drug Metabolism Enzymes and MDR1 Using a Novel Human Hepatocyte Cell Line , 2004, Journal of Pharmacology and Experimental Therapeutics.

[32]  Frank Stahl,et al.  Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. , 2003, Drug metabolism and disposition: the biological fate of chemicals.

[33]  Jos H Beijnen,et al.  An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. , 2003, Toxicology and applied pharmacology.

[34]  P. Krammer,et al.  Immune escape of tumors: apoptosis resistance and tumor counterattack , 2002, Journal of leukocyte biology.

[35]  J. Ku,et al.  Establishment and characterization of four human hepatocellular carcinoma cell lines containing hepatitis B virus DNA. , 1999, World journal of gastroenterology.

[36]  J. Whang‐Peng,et al.  Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. , 1998, British Journal of Cancer.

[37]  V. Caron,et al.  United states. , 2018, Nursing standard (Royal College of Nursing (Great Britain) : 1987).